Meine Merkliste  

199 Aktuelle Fachpublikationen in Cancer Gene Therapy


Sie können Ihre Recherche weiter verfeinern. Wählen Sie aus dem linken Bereich passende Suchfilter aus, um Ihre Ergebnisse gezielt einzugrenzen.

MicroRNA21 and the various types of myeloid leukemia

25.05.2018 | Mani Panagal; Senthil Kumar S. R.; Sivakurunathan P.; Biruntha M.; Karthigeyan M.; Vincent Gopinathe; Pethanen Sivak ..., Cancer Gene Therapy, 2018

Myeloid leukemia (ML) is heterogeneous cancer classified by abnormal growth of myeloid cells due to genetic aberrations and mutations. It is generally categorized by clonal disorders of hematopoietic stem cells and differentiation. The molecular mechanism behind the myeloid malignancies is not ...


Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA combined with cisplatin inhibits cellular growth and induces apoptosis in HPV-positive head and neck cancer cells

24.05.2018 | Yasutaka Kojima; Naoki Otsuki; Mie Kubo; Junko Kitamoto; Eri Takata; Hiroki Saito; Kyoko Kosaka; Naoya Morishita; Na ..., Cancer Gene Therapy, 2018

Human papillomavirus (HPV) infection has been identified as an etiologic factor of head and neck cancers (HNCs). We explored the potential use of antisense HPV RNA transcripts for gene therapy and its effect in combination with cisplatin (CDDP) for HPV-positive HNCs. We introduced the antisense ...


Endostatin gene therapy delivered by attenuated Salmonella typhimurium in murine tumor models

14.05.2018 | Kang Liang; Qing Liu; Pei Li; Yue Han; Xiaoping Bian; Yibo Tang; Qingke Kong, Cancer Gene Therapy, 2018

Salmonella typhimurium (hereafter S. typhimurium), as Gram-negative facultative anaerobic bacteria, are good candidates for cancer therapy and delivering therapeutic antitumor agents. However, it is necessary to reduce the virulence of such bacteria and enhance their tumor-targeting ability, and ...


Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma

14.05.2018 | John A. Barrett; Hongliang Cai; John Miao; Pranay D. Khare; Paul Gonzalez; Jessica Dalsing-Hernandez; Geeta Sharma; ..., Cancer Gene Therapy, 2018

The purpose of this study was to determine if localized delivery of IL-12 encoded by a replication-incompetent adenoviral vector engineered to express IL-12 via a RheoSwitch Therapeutic System® (RTS®) gene switch (Ad-RTS-IL-12) administered intratumorally which is inducibly controlled by the oral ...


Genomic landscape and prognostic analysis of mantle cell lymphoma

14.05.2018 | Ping Yang; Weilong Zhang; Jing Wang; Yuanyuan Liu; Ran An; Hongmei Jing, Cancer Gene Therapy, 2018

To gain insight into the molecular pathogenesis of patients with mantle cell lymphoma (MCL), next-generation whole-exome sequencing of 16 MCL patients was performed. We identified recurrent mutations in genes that are well known to be functionally relevant in MCL, including ATM (37.5%), TP53 ...


Recombinant viruses with other anti-cancer therapeutics: a step towards advancement of oncolytic virotherapy

08.05.2018 | Geetanjali Lal; Maitreyi S. Rajala, Cancer Gene Therapy, 2018

Cancer as a disease is a multifaceted foe which sometimes succumbs to the prescribed treatment and sometimes develops resistance against various therapies. Conventional cancer therapies suffer from many limitations, the least of which is their specificity and systemic side effects. In a majority ...


Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer

08.05.2018 | Kazuho Inoko; Kei Hiraoka; Akihito Inagaki; Mizuna Takahashi; Toshihiro Kushibiki; Koji Hontani; Hironobu Takano; Sh ..., Cancer Gene Therapy, 2018

Toca 511, a retroviral replicating vector (RRV) encoding the yeast cytosine deaminase (yCD) prodrug activator gene, which mediates conversion of the prodrug 5-fluorocytosine (5-FC) to the anticancer drug 5-fluorouracil (5-FU), is currently being evaluated in Phase II/III clinical trials for ...


Synergistic antitumour effects of rapamycin and oncolytic reovirus

03.05.2018 | Charles Comins; Guy Richard Simpson; William Rogers; Kate Relph; Kevin Harrington; Alan Melcher; Victoria Roulstone; ..., Cancer Gene Therapy, 2018

There are currently numerous oncolytic viruses undergoing clinical trial evaluation in cancer patients and one agent, Talimogene laherparepvec, has been approved for the treatment of malignant melanoma. This progress highlights the huge clinical potential of this treatment modality, and the focus ...


CRISPR/Cas9 genome editing technology significantly accelerated herpes simplex virus research

25.04.2018 | Dong Wang; Xian-Wang Wang; Xiao-Chun Peng; Ying Xiang; Shi-Bao Song; Ying-Ying Wang; Lin Chen; Victoria W. Xin; Yan- ..., Cancer Gene Therapy, 2018

Herpes simplex viruses (HSVs) are important pathogens and ideal for gene therapy due to its large genome size. Previous researches on HSVs were hampered because the technology to construct recombinant HSVs were based on DNA homology-dependent repair (HDR) and plaque assay, which are inefficient, ...


Gene expression profiles reveal key genes for early diagnosis and treatment of adamantinomatous craniopharyngioma

23.04.2018 | Jun Yang; Ziming Hou; Changjiang Wang; Hao Wang; Hongbing Zhang, Cancer Gene Therapy, 2018

Adamantinomatous craniopharyngioma (ACP) is an aggressive brain tumor that occurs predominantly in the pediatric population. Conventional diagnosis method and standard therapy cannot treat ACPs effectively. In this paper, we aimed to identify key genes for ACP early diagnosis and treatment. ...


Seite 1 von 20
Suche per e-Mail abonnieren

Sie erhalten passend zu Ihrer Suche die neusten Suchergebnisse per E-Mail. Dieser Service ist für Sie kostenlos und kann jederzeit abbestellt werden.

Ihr Bowser ist nicht aktuell. Microsoft Internet Explorer 6.0 unterstützt einige Funktionen auf Chemie.DE nicht.